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senting for infrainguinal bypass graft in that same time
period.
METHODS
From 1986 to 1998, all patients presenting with both
upper and lower extremity chronic ischemia to Albany
Medical Center were prospectively entered into a vascular
surgery registry. A retrospective review was undertaken to
evaluate demographics, indications, outcomes, and
patency in this cohort. Patients presenting with embolus,
pseudoaneurysm, or trauma were excluded. For the upper
extremity group, involvement of the brachial artery with
occlusive disease was necessary for inclusion in this study.
This occlusive disease was atherosclerotic in origin and was
based on clinical setting, arteriographic findings, and gross
pathology. Arteritis was never an etiology in this series
based on clinical observation.
Patients with upper extremity symptoms were evalu-
ated in our center with pulse volume recordings (PVRs)
after we obtained an appropriate history from all patients
and they underwent a physical examination. This included
finger plethysmography in the setting of gangrene.
Additionally, patients with exertional symptoms under-
went PVR analysis after repetitive arm movement for any
difference from their resting state. If the results were
abnormal, individuals with rest pain or tissue loss under-
went arteriography. Patients with exertional symptoms
were observed with routine follow-up over several
months. If this claudication-equivalent worsened or
remained lifestyle limiting in the setting of abnormal PVR
findings, arteriography was undertaken.
Autogenous conduit was preferred in limb-threatening
Upper extremity ischemia that requires surgical inter-
vention accounts for approximately 4% of all vascular sur-
gical procedures.1,2 Revascularization of the upper
extremity was initially reported by Garrett et al in 1965.3
Since that time, several authors have described their expe-
rience with this uncommon entity.4-10 Compared with
published data on lower extremity revascularization, no
one large series of upper extremity reconstruction cur-
rently exists. 
Upper extremity pathology differs markedly from the
lower extremity. Though occlusive disease is seen in the
upper extremity distal to the axillary artery, it is more
common to have emboli, trauma (iatrogenic or noniatro-
genic), collagen vascular disease, and thromboangiitis
obliterans. Limb loss is rare. Surgical intervention is
required much less because of the abundance of collateral
circulation around the shoulder.
In this study, we evaluated our results with vascular
reconstruction in patients who presented with sympto-
matic atherosclerotic occlusive disease encompassing the
brachial artery. We compared them with all patients pre-
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Objective: Symptomatic arterial disease of the upper extremity is an uncommon problem. In this study, we evaluate our
results with brachial artery reconstruction in patients who present with symptomatic atherosclerotic occlusive disease
and compare this cohort’s demographics with a similar group with lower extremity ischemia.
Methods: From 1986 to 1998, all patients presenting for upper extremity revascularization with chronic ischemia were
prospectively entered into a vascular registry. Demographics, indications, outcomes, and patency were recorded.
Patients presenting with embolus, pseudoaneurysm, or trauma were excluded. The Fisher exact and Student t tests were
used to assess significance.
Results: Fifty-one (83%) bypass grafts were performed with autogenous conduit and the remainder with polytetrafluo-
roethylene. Indications included 18 (30%) patients with exertional arm pain, 35 (57%) with rest pain, and 8 (13%) with
tissue loss. Twenty-five (45%) patients were male, 8 (14%) had diabetes, and 30 (54%) were smokers. The mean age was
58 years (range, 33-93). The operative mortality rate was 1.8%, and follow-up ranged from 1 to 140 months. Eight
occlusions were identified, with six occurring early. Five of these were in women with a smoking history. Only one of
the 26 reconstructions that did not cross a joint occluded, whereas bypass grafts that did cross a joint occluded more
frequently. No other major complications were recognized.
Conclusion: Arm revascularization for ischemia can be performed with reasonable mortality and morbidity rates. These
patients may represent a different subgroup of atherosclerotic disease than those with lower extremity involvement:
they are more commonly women and smokers and less likely to be diabetic. (J Vasc Surg 2001;33:802-5.)
ischemia whenever available and of appropriate size match.
All patients revascularized for an exertional indication had
an autogenous conduit used. Greater saphenous vein was
preferred, although arm vein is an acceptable alternative.
All tunneling was preclavicular, not anatomic, and per-
formed through a tunneling device placed subcutaneously.
PVRs were repeated immediately postoperatively. All
patients were seen in follow-up at regularly scheduled
intervals with duplex scan and PVR evaluation of their
grafts. After the initial comparison, all data were then
restratified by risk factor analysis for further evaluation and
comparison. Complications were tabulated, and statistical
analysis was performed with the Fisher exact and Student t
tests assuming significance for P less than .05. Life-table
analysis was used in determining patency rates. 
RESULTS
In the upper extremity, 61 bypass grafts were per-
formed in 56 patients during the 12-year time period. The
patients’ mean age was 58 years (range, 33-93). Thirty-
one (55.4%) of the patients were women. Demographics
revealed 41 (73%) smokers, 28 (50%) patients with coro-
nary artery disease, 26 (46%) patients with hypertension,
7 (13%) patients with diabetes, and 4 (7%) patients with
end-stage renal disease. They are listed in Table I.
Indications for bypass graft included exertional arm pain
in 18 (30%), rest pain in 35 (57%), and tissue loss in 8
(13%). Fifty-one (83%) bypass grafts were performed with
autogenous conduit and the remainder with polytetraflu-
oroethylene (PTFE). All procedures are listed in Table II.
Follow-up averaged 23.2 ± 7.3 months (range, 1-140).
There was one postoperative death, which was of cardiac
origin, resulting in a 30-day operative mortality rate of
1.8%. There were six early occlusions (10%) and two late
occlusions (3.3%). These are detailed in Table III. There
was one postoperative wound infection (1.8%) and no
limb loss. The late occlusions occurred in patients who
had PTFE bypass grafts taken from across the shoulder
joint to the brachial artery. One patient had an occlusion
at 5 months, which was revised to a vein bypass graft. This
bypass graft occluded in 1 day, and no further surgery was
performed. The second patient had a bypass graft that
occluded at 8 months. This was revised to a vein bypass
graft and is still patent. Of the 56 patients who had upper
extremity occlusive disease, 29 (48%) of them had lower
extremity occlusive disease. This is in marked contrast to
those patients with lower extremity occlusive disease; that
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is, only 1.5% of the nearly 4000 patients who underwent
lower extremity bypass graft required upper extremity
revascularization. 
Life-table analysis revealed a patency of 90.5% for all
bypass grafts at 1 year. Limb salvage was 100%. Looking 
at subgroups, we noticed all late occlusions occurred in
PTFE bypass grafts across the shoulder. Seven of the eight
occlusions in follow-up were seen in female smokers, and
the eighth occurred in a male smoker. As others have iden-
tified, we found that bypass grafts that crossed a joint fared
worse than those that did not.11 There were 25 (96%) of
26 patent bypass grafts at 1 year that did not cross a 
joint. On the other hand, only 28 (80%) of 35 bypass
grafts were patent in this same time period that did cross
a joint (P = .07). Along the same lines, vein bypass grafts
had a trend toward better patency, but no statistically sig-
nificant difference; that is, 46 (90%) of 51 vein bypass
grafts were patent at 1 year compared with 7 (70%) of 10
PTFE bypass grafts (P = .09). Patency rates are listed in
Table IV.
We then compared the results of upper extremity
revascularization with all lower extremity bypass grafts
done in this same time period. No direct correlation can
be made between these two groups. However, lower
extremity reconstruction is more common to most
involved in this surgery and therefore can be a reference
point for comparison. This is summarized in Table V.
There were 3886 patients in this second group. Males
comprised 63.6%; patients with diabetes, 52%; and smok-
ers, 36%. The mean age was 68 years. All of these were sig-
nificantly different from that seen in the brachial bypass
graft group. There was no difference in the use of pros-
thetic conduit. Statistically, the incidence of early occlu-
sion (technical) occurred equally to that seen in the lower
extremity group, whereas late occlusions were identified
less often. Limb loss was not different statistically.
DISCUSSION
Disease of the brachial artery that requires surgical
intervention is simultaneously not uncommon but far
from an everyday occurrence. Because of the relative infre-
quency of this type of disease, authors of previously pub-
lished reports have based their conclusions on relatively
few numbers of cases.4-7 This report is, to our knowledge,
one of the largest reported series of these type of recon-
Table I. Demographics
No. Percent
Smoking 41 73
Coronary artery disease 28 50
Hypertension 26 46
Male 24 45
Diabetes 7 13
End-stage renal disease 4 7
Table II. Type of bypass graft performed
Bypass graft type Vein PTFE Total
Brachial-brachial 23 1 24
Brachial-radial 5 0 5
Brachial-ulnar 4 0 4
Common carotid artery–brachial 9 5 14
Axillary-brachial 5 3 8
Subclavian-brachial 2 1 3
Axillary graft–brachial 1 0 1
Brachial graft–brachial 2 0 2
structions; nevertheless, the absolute number of cases is
not great enough to derive statistical significance from any
one observation.
Compared with lower extremity vascular disease, the
most striking difference is in the demographics of this
patient group. There appeared to be an inordinately large
percentage of female patients (55.4%). Patients presented
at an early age (average, 58 years). In addition, diabetes
was relatively less prevalent (13%). The incidence of hyper-
tension, renal disease, and coronary arterial disease did not
appear markedly different from that seen in lower extrem-
ity arterial disease groups. It was likely that patients pre-
senting with symptomatic upper extremity disease also
have significant synchronous lower extremity occlusive
disease (48% in this series), whereas the converse is clearly
not the case (1.5%). One presumes that this reflects a more
aggressive form of disease that affects a wider swath of the
arterial tree while presenting at a younger age.
The indications for surgery were frequently exertional
arm pain (claudication equivalent) (30%). This prevalence
in the context of a lower extremity series would clearly be
excessive. Lower extremity claudication is generally
treated conservatively because of the relatively benign
nature of the disease and the incidence of postoperative
morbidity and mortality with operative intervention. This
is also true in most patients with upper extremity exer-
tional pain. However, the low postoperative mortality
(1.8%), morbidity (11.5%), and nonexistent limb loss rates
would seem to justify operative intervention in the upper
extremity in the face of exertional symptoms. This said, it
is still true that most patients with such a degree of disease
may be treated without operation.
Of the remaining patients in the reported group, rela-
tively few presented with digital gangrene (13%). Of these
eight patients, all had significant renal disease treated with
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Table III. Occlusions
Original diagnosis Bypass Graft Redo procedure When Outcome
Early
Exertional arm pain Brachial-brachial Vein Graft-brachial 2 d Patent at 4 mo
bypass with vein, 
thrombectomy
Exertional arm pain* Common carotid to Vein None 1 d No further surgery
brachial
Exertional arm pain Brachial-radial Vein Brachial-graft 1 d Patent at 32 mo
bypass with vein
Rest pain Subclavian-brachial Vein Thrombectomy 1 d Died at 5 mo
with vein patch 
Rest pain Common carotid to Vein Exc. missing valve 1 d Patent at 16 mo
brachial
Rest pain Common carotid to PTFE Thrombectomy 7 d Died at 3 mo, patent
brachial
Late
Rest pain Common carotid to PTFE Vein bypass 8 mo Patent at 4 mo
brachial
Rest pain* Axillary-brachial PTFE Common carotid 5 mo Revised to vein bypass
to brachial bypass 
w/vein
*Same patient.
Table IV. Comparison of 1-year patency data
No. Primary patency Secondary patency
All bypass grafts 61 87% (53) 98% (60)
Bypass grafts not crossing a joint 26 96% (25) 100% (26)
Bypass grafts crossing a joint 35 80% (28) 97% (34)
Vein bypass grafts 51 90% (46) 98% (50)
PTFE bypass grafts 10 70% (7) 80% (8)
Table V. Comparative demographics
Infrain-
guinal 
Brachial bypass 
bypass graft graft P value
Male 44.6% (25) 63.6% .002
Diabetic 13% (7) 52% < .001
Smoker 73% (41) 36% < .001
Mean age (y) 56 68 < .001
Prosthetic 17% (10) 20.4% .51
Early occlusions 10% (6) 4.9% .07
Late occlusions 3.3% (2) 11.6% .04
30-day limb loss 0% (0) 1.8% .29
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dialysis or transplant. These patients required the most
distal reconstructions to the ulnar or radial arteries. In
contradistinction to the results seen in lower extremity dis-
ease in the dialysis/transplant population, all patients with
bypass grafts had improvement of their symptoms, sur-
vived the operation, and maintained bypass graft patency.
Although a small group overall, these individuals may well
need to be offered reconstruction more aggressively than
is currently thought.
After upper extremity revascularization, this patient
population had reasonable patency. Bypass graft perfor-
mance in this group tended to follow some of the same
principles seen in a typical lower extremity bypass graft
series. Autogenous grafts performed somewhat better
than PTFE grafts, although the numbers were too small to
generate statistical significance. Bypass grafts that crossed
a joint, especially the common carotid, subclavian, or axil-
lary artery to brachial reconstructions, performed the
most poorly in this series. We think that the tunneling of
these bypass grafts in the region of the shoulder may be
problematic, because it is difficult to tunnel anatomically,
whereas the usual extra-anatomic tunnel along the ante-
rior and superior aspects of the shoulder may predispose
the graft to kinking with arm abduction or adduction.
Fortunately, no limbs were lost in the patients who had
bypass grafts that occluded. Offering a bypass graft that
crosses a joint in the arm for exertional symptoms should
be done somewhat cautiously because the results of
surgery may not be ideal.
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CORRECTION
In: “Recommended standards for reports dealing with lower extremity ischemia: Revised version (Rutherford
RB, Baker DJ, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN Jr. J Vasc Surg 1997;26:517-38).
The footnote to Tables IV (p. 526) and V (p. 528) contains an error. The last line of each foot note should indi-
cate division by column B rather than column C and read as follows: Column G = F × √{(1 - [F/100]/B}. The
corresponding text on page 527 should then read as follows: (G) Standard errors in percent are calculated as F ×
square root of {(1 – (F/100))/B}, where F equals the cumulative patency rate in percent and B is the number at risk
at the start of the interval.
Comment: This estimate of the standard error for both Life Table and Kaplan-Meier survival curves is consistent
with that proposed by Peto et al (ref 28): standard error = pχ√{(1 – p)n)} where p = survival probability, 1 – p = prob-
ability of failure, and n = number at risk. 
